Identification

Name
Budesonide
Accession Number
DB01222  (APRD00442)
Type
Small Molecule
Groups
Approved
Description

Budesonide is a glucocorticoid used in the management of asthma, the treatment of various skin disorders, and allergic rhinitis. [PubChem] The extended release oral tablet, marketed as Uceris, was FDA approved on January 14, 2013 for the management of ulcerative colitis. Budesonide is provided as a mixture of two epimers (22R and 22S). Interestingly, the 22R form is two times more active than the 22S epimer. The two forms do not interconvert.

Structure
Thumb
Synonyms
  • (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BudesonideSpray, metered32 ug/1NasalAstra Zeneca Lp2014-05-132018-02-28Us
BudesonideSpray, metered32 ug/1NasalPar Pharmaceutical2014-10-212017-01-10Us
BudesonideCapsule3 mg/1OralPar Pharmaceutical2011-08-18Not applicableUs49884 0501 01 nlmimage10 eb3975bb
CortimentTablet, extended release9 mgOralFerring Pharmaceuticals2016-07-25Not applicableCanada
EntocortCapsule, extended release3 mgOralTillotts Pharma Gmbh1997-01-30Not applicableCanada
Entocort ECCapsule3 mg/1OralAstra Zeneca Lp2001-10-02Not applicableUs
Entocort ECCapsule3 mg/1OralPaddock Laboratories, Inc.2001-10-29Not applicableUs
Entocort ECCapsule3 mg/1OralPrometheus Laboratories2001-10-29Not applicableUs
Entocort ECCapsule3 mg/1OralPhysicians Total Care, Inc.2006-05-22Not applicableUs65483 0702 10 nlmimage10 f6387b33
Mylan-budesonide AQSpray, metered100 mcgNasalMylan Pharmaceuticals1997-02-12Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BudesonideSuspension.25 mg/2mLRespiratory (inhalation)Sandoz2015-07-24Not applicableUs
BudesonideCapsule3 mg/1OralMylan Institutional2011-09-02Not applicableUs
BudesonideSuspension.25 mg/2mLRespiratory (inhalation)Preferreed Pharmaceuticals Inc.2017-10-11Not applicableUs
BudesonideSuspension.5 mg/2mLRespiratory (inhalation)Dispensing Solutions, Inc.2008-11-19Not applicableUs
BudesonideSuspension.5 mg/2mLRespiratory (inhalation)Cardinal Health2009-12-15Not applicableUs
BudesonideSuspension.5 mg/2mLRespiratory (inhalation)Preferreed Pharmaceuticals Inc.2009-02-04Not applicableUs
BudesonideCapsule3 mg/1OralMylan Pharmaceuticals2011-05-16Not applicableUs
BudesonideSuspension.5 mg/2mLRespiratory (inhalation)Preferreed Pharmaceuticals Inc.2016-11-03Not applicableUs
BudesonideCapsule, gelatin coated3 mg/1OralAmneal Pharmaceuticals2017-09-15Not applicableUs
BudesonideSuspension1 mg/2mLRespiratory (inhalation)Teva2016-03-11Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BudesonideSpray, metered32 ug/1NasalApotex Corporation2016-04-19Not applicableUs
BudesonideSpray, metered32 ug/1NasalRite Aid2016-07-13Not applicableUs
BudesonideSpray, metered32 ug/1NasalCVS Health2016-04-09Not applicableUs
BudesonideSpray, metered32 ug/1NasalSafeway2016-09-15Not applicableUs
BudesonideSpray, metered32 ug/1NasalTopco Associates2016-08-31Not applicableUs
BudesonideSpray, metered32 ug/1NasalRugby2016-07-13Not applicableUs
BudesonideSpray, metered32 ug/1NasalWalgreens2016-04-11Not applicableUs
BudesonideSpray, metered32 ug/1NasalAmerisource Bergen2016-09-15Not applicableUs
BudesonideSpray, metered32 ug/1NasalWalmart2016-08-22Not applicableUs
Childrens RHINOCORT AllergySpray, metered32 ug/1NasalJohnson & Johnson Consumer Inc., Mc Neil Consumer Healthcare Division2017-01-16Not applicableUs
International/Other Brands
Bidien / Budeson / Budicort / ENTOCORT / Noex (Eurofarma) / Pulmicort (AstraZeneca) / Rhinocort (AstraZeneca) / Rhinosol / Spirocort
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Budesonide/formoterol TevaBudesonide (320 μg / dose)Respiratory (inhalation)Teva Pharma B.V.2014-11-19Not applicableEu
Budesonide/formoterol TevaBudesonide (160 μg / dose)Respiratory (inhalation)Teva Pharma B.V.2014-11-19Not applicableEu
Entocort EnemaBudesonide (2.3 mg) + Sodium Chloride (115 ml)Enema; Kit; TabletRectalTillotts Pharma Gmbh1994-12-31Not applicableCanada
SymbicortBudesonide (160 ug/1) + Formoterol fumarate (4.5 ug/1)AerosolRespiratory (inhalation)Astra Zeneca Lp2007-05-29Not applicableUs
SymbicortBudesonide (160 ug/1) + Formoterol fumarate (4.5 ug/1)AerosolRespiratory (inhalation)Remedy Repack2016-04-042017-02-23Us
SymbicortBudesonide (160 ug/1) + Formoterol fumarate (4.5 ug/1)AerosolRespiratory (inhalation)A S Medication Solutions2007-05-292017-06-20Us
SymbicortBudesonide (80 ug/1) + Formoterol fumarate (4.5 ug/1)AerosolRespiratory (inhalation)Astra Zeneca Lp2007-05-29Not applicableUs
Symbicort 100 TurbuhalerBudesonide (100 mcg)PowderRespiratory (inhalation)Astra Zeneca2002-02-08Not applicableCanada
Symbicort 200 TurbuhalerBudesonide (200 mcg)PowderRespiratory (inhalation)Astra Zeneca2002-02-08Not applicableCanada
Symbicort Forte TurbuhalerBudesonide (400 mcg)PowderRespiratory (inhalation)Astra ZenecaNot applicableNot applicableCanada
Categories
UNII
Q3OKS62Q6X
CAS number
51333-22-3
Weight
Average: 430.5339
Monoisotopic: 430.23553882
Chemical Formula
C25H34O6
InChI Key
VOVIALXJUBGFJZ-KWVAZRHASA-N
InChI
InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
IUPAC Name
(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-14,17-dien-16-one
SMILES

Pharmacology

Indication

The oral capsule is used for the treatment of mild to moderate active Crohn's disease. The oral tablet is used for induction of remission in patients with active, mild to moderate ulcerative colitis. The oral inhalation formulation is used for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis.

Structured Indications
Pharmacodynamics

Budesonide has a high glucocorticoid effect and a weak mineralocorticoid effect. It binds to the glucocorticoid receptor with a higher binding affinity than cortisol and prednisolone. When budesonide is systemically administered, suppression of endogenous cortisol concentrations and an impairment of the hypothalamus-pituitary-adrenal (HPA) axis function has been observed. Furthermore, a decrease in airway reactivity to histamine and other entities has been observed with the inhaled formulation. Generally, the inhaled formulation has a rapid onset action and improvement in asthma control can occur within 24 hours of initiation of treatment.

Mechanism of action

Budesonide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineralocorticoid activity. The precise mechanism of corticosteroid actions on inflammation in asthma, Crohn's disease, or ulcerative colitis is not known. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of inhibitory activities against multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (eg, histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic and non-allergic-mediated inflammation. These anti-inflammatory actions of corticosteroids may contribute to their efficacy in the aforementioned diseases. Because budesonide undergoes significant first-pass elimination, the both oral preparations are formulated as an extended release tablet. As a result, budesonide release is delyaed until exposure to a pH ≥ 7 in the small intestine.

TargetActionsOrganism
AGlucocorticoid receptor
antagonist
Human
Absorption

Absorption is complete following oral administration. The pharmacokinetic parameters of the inhaled powder formulation are as follows: Tmax = 30 minutes; Absolute systemic availability = 39%. When a single oral administration of 9 mg of Uceris are given, the pharmacokinetic parameters are as follows: Tmax = 13.3 ± 5.9 hours; Cmax = 1.35 ± 0.96 ng/mL; AUC = 16.43 ± 10.52 ng·hr/mL. It is important to note that the parameters have a high degree of variability. When a single oral administration of Entocort EC are given, the pharmacokinetic parameters are as follows: Tmax = 3- 600 minutes; Cmax = 5 nmol/L; AUC = 30 nmol•hr/L.

Volume of distribution

Tablet and capsule, healthy subjects and patients = 2.2 - 3.9 L/kg; Powder, metered = 3 L/kg

Protein binding

85-90% protein bound.

Metabolism

Following absorption, budesonide is subject to high first pass metabolism (80-90%). Budesonide is rapidly and extensively biotransformed, mainly by CYP3A4, to its 2 major metabolites, 6b-hydroxybudesonide and 16a- hydroxyprednisolone. The glucocorticoid activity of these metabolites is negligible (<1/100) in relation to that of the parent compound.

Route of elimination

Budesonide is excreted in urine and feces in the form of metabolites. Approximately 60% of an intravenous radiolabelled dose was recovered in the urine. No unchanged budesonide was detected in the urine.

Half life

Following IV administration of budesonide, the elimination half-life is 2.0 to 3.6 hours. This value does not differ between healthy adults and patients with Crohn’s disease.

Clearance

Plasma clearance, tablet = 0.9 - 1.8 L/min; Systemic clearance, powder, 22R = 1.4 L/min; Systemic clearance, powder, 22S = 1.0 L/min; 0.5 L/min [Athmatic children 4 to 6 years of age]

Toxicity

Single oral doses of 200 and 400 mg/kg were lethal in female and male mice, respectively. The signs of acute toxicity were decreased motor activity, piloerection and generalized edema.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
T-box transcription factor TBX21---(C;G)CG allele (heterozygotes)Effect Directly StudiedThe presence of this polymorphism in TBX21 may be associated with improved responsiveness to budenoside for the treatment of asthma.Details

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Budesonide is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Budesonide.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Budesonide.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Budesonide.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Budesonide.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Budesonide.Approved, Withdrawn
AldesleukinBudesonide may decrease the antineoplastic activities of Aldesleukin.Approved
AlgeldrateThe bioavailability of Budesonide can be decreased when combined with Algeldrate.Approved, Experimental
AlmagateThe bioavailability of Budesonide can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of Budesonide can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Budesonide.Experimental
AloglutamolThe bioavailability of Budesonide can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Budesonide.Experimental
AluminiumThe bioavailability of Budesonide can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Budesonide can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Budesonide can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Budesonide can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Budesonide is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Budesonide.Approved
AmiodaroneThe serum concentration of Budesonide can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BBudesonide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Budesonide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Budesonide.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Budesonide.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Budesonide.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Budesonide.Approved, Investigational
AprepitantThe serum concentration of Budesonide can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Budesonide can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Budesonide can be increased when it is combined with Atomoxetine.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Budesonide.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Budesonide.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Budesonide.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Budesonide.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Budesonide.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Budesonide.Experimental
BendroflumethiazideBudesonide may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Budesonide.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Budesonide.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Budesonide.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Budesonide.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Budesonide.Experimental
Bismuth SubcitrateThe bioavailability of Budesonide can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Budesonide can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Budesonide can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Budesonide can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Budesonide can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Budesonide.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Budesonide.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Budesonide.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Budesonide.Experimental
BumetanideBudesonide may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Budesonide.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Budesonide can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Budesonide can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideBudesonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe metabolism of Budesonide can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Budesonide.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Budesonide.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Budesonide.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Budesonide.Approved, Investigational
CeritinibThe serum concentration of Budesonide can be increased when it is combined with Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Budesonide.Approved, Vet Approved
ChlorothiazideBudesonide may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Budesonide can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneBudesonide may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Budesonide.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Budesonide can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Budesonide can be increased when it is combined with Clemastine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Budesonide.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Budesonide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClotrimazoleThe serum concentration of Budesonide can be increased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Budesonide can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Budesonide can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Budesonide can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Budesonide.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Budesonide is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Budesonide is combined with Coumaphos.Vet Approved
CrizotinibThe serum concentration of Budesonide can be increased when it is combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Budesonide.Investigational
CyclopenthiazideBudesonide may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclosporineThe serum concentration of Budesonide can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Budesonide.Investigational
DabrafenibThe serum concentration of Budesonide can be decreased when it is combined with Dabrafenib.Approved
DaidzeinThe serum concentration of Budesonide can be increased when it is combined with Daidzein.Experimental
DanazolBudesonide may increase the fluid retaining activities of Danazol.Approved
DarunavirThe serum concentration of Budesonide can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Budesonide can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Budesonide is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Budesonide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Budesonide can be increased when it is combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Budesonide is combined with Demecarium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Budesonide.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Budesonide.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Budesonide is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Budesonide.Approved, Vet Approved
DienestrolThe serum concentration of Budesonide can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Budesonide can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Budesonide.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Budesonide.Approved
DihydroergotamineThe serum concentration of Budesonide can be increased when it is combined with Dihydroergotamine.Approved
DihydrotestosteroneBudesonide may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe serum concentration of Budesonide can be increased when it is combined with Diltiazem.Approved
DistigmineThe risk or severity of adverse effects can be increased when Budesonide is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Budesonide is combined with Donepezil.Approved
DoxycyclineThe serum concentration of Budesonide can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Budesonide can be increased when it is combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Budesonide.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Budesonide.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Budesonide.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Budesonide is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Budesonide is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Budesonide can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Budesonide can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Budesonide.Approved
EquolThe serum concentration of Budesonide can be increased when it is combined with Equol.Investigational
ErythromycinThe serum concentration of Budesonide can be increased when it is combined with Erythromycin.Approved, Vet Approved
EstradiolThe serum concentration of Budesonide can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Budesonide can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Budesonide can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Budesonide can be increased when it is combined with Estrone.Approved
Etacrynic acidBudesonide may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Budesonide.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Budesonide.Experimental
Ethinyl EstradiolThe serum concentration of Budesonide can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Budesonide.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Budesonide.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Budesonide.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Budesonide.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Budesonide.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Budesonide.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Budesonide.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Budesonide.Approved
FenthionThe risk or severity of adverse effects can be increased when Budesonide is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Budesonide.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Budesonide.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Budesonide.Experimental
FingolimodBudesonide may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Budesonide.Approved, Withdrawn
FluconazoleThe serum concentration of Budesonide can be increased when it is combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Budesonide is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Budesonide.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Budesonide.Experimental
FluoxymesteroneBudesonide may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Budesonide.Approved, Investigational
FluvoxamineThe serum concentration of Budesonide can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Budesonide can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Budesonide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Budesonide can be increased when combined with Fosphenytoin.Approved
FurosemideBudesonide may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Budesonide can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Budesonide is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Budesonide is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Budesonide is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Budesonide can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Budesonide is combined with GI-5005.Investigational
GLPG-0492Budesonide may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Budesonide.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Budesonide.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Budesonide.Experimental
HexestrolThe serum concentration of Budesonide can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Budesonide.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Budesonide is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Budesonide.Approved, Investigational
HydrochlorothiazideBudesonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideBudesonide may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Budesonide can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Budesonide.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Budesonide.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Budesonide.Approved
IdelalisibThe serum concentration of Budesonide can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Budesonide can be increased when it is combined with Imatinib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Budesonide.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Budesonide.Approved
IndapamideBudesonide may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Budesonide can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Budesonide.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Budesonide.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Budesonide.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Budesonide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Budesonide is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Budesonide is combined with Ipidacrine.Experimental
IsavuconazoniumThe serum concentration of Budesonide can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Budesonide is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Budesonide.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Budesonide.Withdrawn
IsradipineThe serum concentration of Budesonide can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Budesonide can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Budesonide can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Budesonide.Experimental
KetoconazoleThe serum concentration of Budesonide can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Budesonide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Budesonide.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Budesonide is combined with Leflunomide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Budesonide.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Budesonide.Experimental
LopinavirThe serum concentration of Budesonide can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Budesonide.Approved, Investigational
LovastatinThe serum concentration of Budesonide can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Budesonide is combined with Loxapine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Budesonide.Approved, Investigational
LuliconazoleThe serum concentration of Budesonide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Budesonide can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Budesonide.Approved, Investigational
MagaldrateThe bioavailability of Budesonide can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Budesonide can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Budesonide can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Budesonide can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Budesonide.Approved
Magnesium silicateThe bioavailability of Budesonide can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Budesonide can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Budesonide is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Budesonide.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Budesonide.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Budesonide.Approved
MefloquineThe risk or severity of adverse effects can be increased when Budesonide is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Budesonide.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Budesonide is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Budesonide.Approved
MesteroloneBudesonide may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Budesonide can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Budesonide.Investigational, Withdrawn
MethallenestrilThe serum concentration of Budesonide can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Budesonide is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideBudesonide may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Budesonide.Approved, Vet Approved
MethyltestosteroneBudesonide may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Budesonide is combined with Metoclopramide.Approved, Investigational
MetolazoneBudesonide may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe serum concentration of Budesonide can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Budesonide is combined with Minaprine.Approved
MitotaneThe serum concentration of Budesonide can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Budesonide.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Budesonide.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Budesonide.Experimental
MoxestrolThe serum concentration of Budesonide can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Budesonide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Budesonide.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Budesonide.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Budesonide.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Budesonide.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Budesonide is combined with Nalidixic Acid.Approved, Investigational
NandroloneBudesonide may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateBudesonide may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Budesonide.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Budesonide is combined with Natalizumab.Approved, Investigational
NefazodoneThe serum concentration of Budesonide can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Budesonide can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Budesonide is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Budesonide.Approved
NetupitantThe serum concentration of Budesonide can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Budesonide can be increased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Budesonide is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Budesonide.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Budesonide.Approved
NilotinibThe serum concentration of Budesonide can be increased when it is combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Budesonide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Budesonide.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Norfloxacin.Approved
OlaparibThe serum concentration of Budesonide can be increased when it is combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Budesonide.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Budesonide.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Budesonide.Vet Approved
OsimertinibThe serum concentration of Budesonide can be increased when it is combined with Osimertinib.Approved
OxandroloneBudesonide may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Budesonide.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Budesonide is combined with Oxolinic acid.Experimental
OxymetholoneBudesonide may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Budesonide.Approved, Withdrawn
PalbociclibThe serum concentration of Budesonide can be increased when it is combined with Palbociclib.Approved
ParaoxonThe risk or severity of adverse effects can be increased when Budesonide is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Budesonide.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Budesonide.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Pefloxacin.Approved
PentobarbitalThe metabolism of Budesonide can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Budesonide can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Budesonide.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Budesonide.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Budesonide.Approved, Investigational
PhenytoinThe metabolism of Budesonide can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Budesonide is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Budesonide.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Budesonide is combined with Pipemidic acid.Experimental
PiretanideBudesonide may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Budesonide.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Budesonide is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Budesonide.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Budesonide.Experimental
Polyestradiol phosphateThe serum concentration of Budesonide can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideBudesonide may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Budesonide can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Budesonide.Experimental, Investigational
PrimidoneThe metabolism of Budesonide can be increased when combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Budesonide.Experimental
PromestrieneThe serum concentration of Budesonide can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Budesonide.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Budesonide.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Budesonide.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Budesonide.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Budesonide is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Budesonide can be increased when it is combined with Quinestrol.Approved
QuinethazoneBudesonide may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Budesonide is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Budesonide.Approved
RanolazineThe serum concentration of Budesonide can be increased when it is combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Budesonide.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Budesonide.Approved, Experimental, Investigational
RibociclibThe serum concentration of Budesonide can be increased when it is combined with Ribociclib.Approved
RifabutinThe metabolism of Budesonide can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Budesonide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Budesonide can be increased when combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Budesonide is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Budesonide is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Budesonide.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Budesonide.Approved
RosoxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Budesonide is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Budesonide is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Budesonide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Budesonide.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Budesonide.Approved
SaquinavirThe serum concentration of Budesonide can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Budesonide can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Budesonide.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Budesonide.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Budesonide.Investigational
SildenafilThe serum concentration of Budesonide can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Budesonide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Budesonide can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Budesonide.Approved
SitafloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of Budesonide can be decreased when combined with Sodium bicarbonate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Budesonide is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Budesonide.Investigational
St. John's WortThe serum concentration of Budesonide can be decreased when it is combined with St. John&#39;s Wort.Investigational, Nutraceutical
StanozololBudesonide may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Budesonide can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Budesonide.Approved
SulfisoxazoleThe serum concentration of Budesonide can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Budesonide.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Budesonide.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Budesonide.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Budesonide can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Budesonide can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Budesonide is combined with Tacrine.Investigational, Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Budesonide.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Budesonide.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Budesonide is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Budesonide can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Budesonide can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Budesonide.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Budesonide.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Budesonide.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Budesonide.Approved
TestosteroneBudesonide may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone PropionateBudesonide may increase the fluid retaining activities of Testosterone Propionate.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Budesonide is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Budesonide.Approved
TiboloneThe serum concentration of Budesonide can be increased when it is combined with Tibolone.Approved, Investigational
TiclopidineThe serum concentration of Budesonide can be increased when it is combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Budesonide.Investigational
TocilizumabThe serum concentration of Budesonide can be decreased when it is combined with Tocilizumab.Approved
TofacitinibBudesonide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Budesonide.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Budesonide.Approved
TorasemideBudesonide may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Budesonide.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Budesonide.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Budesonide.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Budesonide is combined with Trichlorfon.Vet Approved
TrichlormethiazideBudesonide may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Budesonide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Budesonide.Approved
TromethamineThe bioavailability of Budesonide can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Budesonide is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Budesonide.Investigational, Withdrawn
VenlafaxineThe serum concentration of Budesonide can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Budesonide can be increased when it is combined with Verapamil.Approved
VoriconazoleThe serum concentration of Budesonide can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinBudesonide may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Budesonide is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Budesonide.Approved, Investigational
ZeranolThe serum concentration of Budesonide can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Budesonide.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Budesonide can be increased when it is combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Budesonide.Withdrawn
Zoster vaccineThe risk or severity of adverse effects can be increased when Budesonide is combined with Zoster vaccine.Approved
Food Interactions
  • A mean delay in time to peak concentration of 2.5 hours is observed with the intake of a high-fat meal, with no significant differences in AUC.

References

Synthesis Reference

Peter Gruber, Hans Joachim Lach, Norbert Otterbeck, "Budesonide pellets with a controlled released pattern and process for producing the same." U.S. Patent US5932249, issued May, 1991.

US5932249
General References
Not Available
External Links
Human Metabolome Database
HMDB15353
KEGG Drug
D00246
PubChem Compound
5281004
PubChem Substance
46504869
ChemSpider
4444479
BindingDB
50354850
ChEBI
3207
ChEMBL
CHEMBL1370
Therapeutic Targets Database
DAP000320
PharmGKB
PA448681
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Budesonide
ATC Codes
R03AK07 — Formoterol and budesonideA07EA06 — BudesonideR03BA02 — BudesonideR01AD05 — BudesonideR03AK12 — Salmeterol and budesonideD07AC09 — Budesonide
AHFS Codes
  • 68:04.00 — Adrenals
  • 52:08.00 — Anti-inflammatory Agents
  • 52:08.08 — Corticosteroids
FDA label
Download (52.3 KB)
MSDS
Download (73.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceAsthma Bronchial1
1CompletedPreventionAcute Chest Syndrome / Asthma Bronchial / Sickle Cell Disorders1
1CompletedTreatmentAllergies1
1CompletedTreatmentAsthma Bronchial6
1CompletedTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)2
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
1CompletedTreatmentLiver Cirrhosis, Biliary / Sclerosing Cholangitis1
1CompletedTreatmentSnoring1
1RecruitingTreatmentGraft Versus Host Disease (GVHD) / Transplantation, Stem Cell1
1, 2CompletedTreatmentAsthma Bronchial1
1, 2RecruitingPreventionBronchopulmonary Dysplasia (BPD)1
2CompletedNot AvailableAsthma Bronchial1
2CompletedPreventionAcute Respiratory Distress Syndrome (ARDS)1
2CompletedPreventionLung Cancers2
2CompletedTreatmentAllergic Rhinitis (AR)1
2CompletedTreatmentAllogeneic Stem Cell Transplantation / Obliterative Bronchiolitis1
2CompletedTreatmentAsthma Bronchial4
2CompletedTreatmentBronchial Asthma1
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)4
2CompletedTreatmentCopd Bronchitis1
2CompletedTreatmentCrohn's Disease (CD)1
2CompletedTreatmentEosinophilic Esophagitis (EoE)1
2CompletedTreatmentExercised Induced Asthma1
2CompletedTreatmentIgA Nephropathy1
2CompletedTreatmentMalignant Melanoma1
2CompletedTreatmentObstructive Airway Disease1
2CompletedTreatmentOesophagitis, Eosinophilic3
2CompletedTreatmentSeasonal Allergic Rhinitis (SAR)3
2CompletedTreatmentStable Asthma1
2CompletedTreatmentUlcerative Colitis (UC)1
2Not Yet RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2RecruitingTreatmentAcute Cellular Graft Rejection / New Onset Diabetes After Transplant1
2RecruitingTreatmentAsthma Bronchial1
2RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2RecruitingTreatmentDiarrhea1
2RecruitingTreatmentEarly Stage HER2+ Breast Cancer1
2RecruitingTreatmentEsophageal Strictures1
2RecruitingTreatmentOesophagitis, Eosinophilic1
2TerminatedPreventionCryptogenic Organizing Pneumonia / Lung Diseases, Interstitial / Obliterative Bronchiolitis / Respiratory Tract Infections (RTI)1
2TerminatedPreventionProphylaxis of Radiation proctitis1
2TerminatedTreatmentInflammatory Bowel Diseases (IBD) / Ulcerative Colitis (UC)1
2Unknown StatusPreventionChronic Lung Disease of Prematurity1
2Unknown StatusTreatmentCrohn's Disease (CD)1
2Unknown StatusTreatmentTransient Tachypnea of the Newborn1
2WithdrawnTreatmentAcute Graft Versus Host Disease / Intestinal Graft Versus Host Disease1
2WithdrawnTreatmentOlfaction Disorders / Paranasal Sinus Diseases / Sinusitis1
2, 3CompletedTreatmentAllergies1
2, 3CompletedTreatmentEE / Gastroesophageal Reflux Disease / GERD / Oesophagitis, Eosinophilic1
2, 3CompletedTreatmentHepatitis, Autoimmune1
2, 3CompletedTreatmentPolyps, Nasal1
2, 3CompletedTreatmentSinusitis1
2, 3CompletedTreatmentStatus Asthmaticus1
2, 3TerminatedTreatmentDiarrhea / Lymphocytic Colitis1
3Active Not RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
3CompletedNot AvailableAsthma Bronchial1
3CompletedPreventionChronic Lung Disease of Prematurity1
3CompletedPreventionGraft Versus Host Disease (GVHD) / Leukemias1
3CompletedPreventionOther and unspecified effects of high altitude1
3CompletedTreatmentAllergic Rhinitis (AR)1
3CompletedTreatmentAsthma Bronchial43
3CompletedTreatmentAsthma Bronchial / Chronic Lung Diseases1
3CompletedTreatmentCOPD Patients1
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)5
3CompletedTreatmentChronic / Chronic Rhinosinusitis / Polyposis / Sinusitis1
3CompletedTreatmentCollagenous Colitis2
3CompletedTreatmentCrohn's Disease (CD)4
3CompletedTreatmentGraft Versus Host Disease (GVHD)1
3CompletedTreatmentInduction and Maintaining Remission of Collagenous Colitis1
3CompletedTreatmentLymphocytic Colitis1
3CompletedTreatmentMicroscopic Colitis1
3CompletedTreatmentMild or Moderate Asthma1
3CompletedTreatmentOesophagitis, Eosinophilic1
3CompletedTreatmentOral Chronic Graft vs Host Disease1
3CompletedTreatmentProctitis / Proctosigmoiditis2
3CompletedTreatmentPulmonary Disease, Chronic Obstructive1
3CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
3CompletedTreatmentUlcerative Colitis (UC)4
3Not Yet RecruitingTreatmentChronic Rhinosinusitis (Diagnosis)1
3Not Yet RecruitingTreatmentRhinitis, Allergic, Perennial2
3RecruitingTreatmentAcute maxillary sinusitis caused by M. catarrhalis1
3RecruitingTreatmentAcute maxillary sinusitis caused by M. catarrhalis / Chronic Polyposis1
3RecruitingTreatmentAsthma Bronchial2
3RecruitingTreatmentAsthma Bronchial / Bioequivalence1
3RecruitingTreatmentBronchial Asthma1
3RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
3RecruitingTreatmentChronic Obstructive Pulmonary Disorder2
3RecruitingTreatmentChronic Rhinosinusitis (Diagnosis), Nasal Polyposis1
3RecruitingTreatmentChronic Rhinosinusitis With Nasal Polyps1
3RecruitingTreatmentEosinophilic Esophagitis (EoE)1
3RecruitingTreatmentOesophagitis, Eosinophilic1
3TerminatedTreatmentPrimary Biliary Cirrhosis (PBC)1
3Unknown StatusTreatmentBronchial Asthma1
3Unknown StatusTreatmentCollagenous Colitis1
3Unknown StatusTreatmentEmphysema / Poor Sleeping Quality1
3WithdrawnPreventionAltitude Sickness1
4CompletedNot AvailableAsthma Bronchial1
4CompletedBasic ScienceChronic Obstructive Pulmonary Disease (COPD)1
4CompletedBasic ScienceMild Asthma1
4CompletedSupportive CareAsthma Bronchial1
4CompletedTreatmentAcute Asthma / Asthma Bronchial / Reactive Airway Exacerbation1
4CompletedTreatmentAcute maxillary sinusitis caused by M. catarrhalis / Allergic Rhinosinusitis / Chronic Eosinophilic Rhinosinusitis1
4CompletedTreatmentAllergic Rhinitis (AR)1
4CompletedTreatmentAsthma Bronchial12
4CompletedTreatmentBronchial Asthma1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)10
4CompletedTreatmentCrohn's Disease (CD)1
4CompletedTreatmentObstructive Sleep Apnea Syndrome (OSAS)1
4CompletedTreatmentPerennial Allergic Rhinitis (PAR)2
4CompletedTreatmentPulmonary Disease, Chronic Obstructive1
4Not Yet RecruitingPreventionChronic Lung Disease of Prematurity / Respiratory Distress Syndrome (RDS)1
4Not Yet RecruitingPreventionChronic Obstructive Pulmonary Disease (COPD) / Lung Cancers / Post Operative Complication, Pulmonary1
4Not Yet RecruitingTreatmentAcute Cellular Graft Rejection / Liver Transplant Rejection1
4Not Yet RecruitingTreatmentAsthma Bronchial1
4RecruitingNot AvailableAsthma Bronchial1
4RecruitingTreatmentAcute Exacerbation of Chronic Obstructive Pulmonary Disease / Chronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentAsthma Bronchial1
4RecruitingTreatmentBronchial Asthma1
4RecruitingTreatmentBronchiectasis / Chronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentHyposmia1
4RecruitingTreatmentOesophagitis, Eosinophilic1
4RecruitingTreatmentPulmonary Disease,Chronic Obstructive1
4RecruitingTreatmentSevere IgE-mediated Asthma1
4TerminatedTreatmentAsthma Bronchial1
4TerminatedTreatmentChronic Obstructive Pulmonary Disease (COPD)2
4TerminatedTreatmentExercised Induced Asthma1
4Unknown StatusPreventionChronic Lung Disease of Prematurity / Respiratory Distress Syndrome (RDS)1
4Unknown StatusTreatmentAsthma Bronchial1
4Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4Unknown StatusTreatmentObstructive Sleep Apnea (OSA)1
4Unknown StatusTreatmentOesophagitis, Eosinophilic1
4WithdrawnNot AvailableBone destruction1
4WithdrawnBasic ScienceAsthma Bronchial1
4WithdrawnTreatmentAsthma Bronchial2
Not AvailableActive Not RecruitingTreatmentAsthma Bronchial1
Not AvailableCompletedNot AvailableAsthma Bronchial3
Not AvailableCompletedNot AvailableAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailablePerception of Physicians & Patients of AMD1
Not AvailableCompletedBasic ScienceAsthma Bronchial2
Not AvailableCompletedDiagnosticAsthma Bronchial1
Not AvailableCompletedHealth Services ResearchAsthma Bronchial1
Not AvailableCompletedTreatmentAsthma Bronchial1
Not AvailableCompletedTreatmentAsthma Bronchial / Chronic Lung Diseases1
Not AvailableCompletedTreatmentPolyps, Nasal / Sinusitis1
Not AvailableRecruitingNot AvailableAsthma Bronchial1
Not AvailableRecruitingNot AvailableCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD)1
Not AvailableRecruitingNot AvailableUlcerative Colitis (UC)1
Not AvailableRecruitingBasic ScienceAsthma Bronchial1
Not AvailableRecruitingPreventionAcute Exacerbation of Chronic Obstructive Pulmonary Disease / Air Pollution1
Not AvailableRecruitingTreatmentChronic Rhinosinusitis / Nasal Polyposis1
Not AvailableTerminatedTreatmentAsthma Bronchial1
Not AvailableTerminatedTreatmentChronic Rhinosinusitis1
Not AvailableTerminatedTreatmentColitis1
Not AvailableUnknown StatusNot AvailableAllergic Rhinitis (AR) / Asthma Bronchial1
Not AvailableUnknown StatusNot AvailableFocus of Study is to Improve Asthma Control Based on Phenotype, NO and Sputum Cell Count1
Not AvailableUnknown StatusPreventionRespiratory Sounds2
Not AvailableUnknown StatusTreatmentAsthma Bronchial2
Not AvailableUnknown StatusTreatmentRespiratory Distress Syndrome (RDS)1
Not AvailableUnknown StatusTreatmentStridor1
Not AvailableWithdrawnTreatmentHepatitis, Autoimmune / Primary Biliary Cirrhosis (PBC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral3 mg/1
Capsule, coated pelletsOral3 mg/1
Capsule, gelatin coatedOral3 mg/1
InhalantRespiratory (inhalation).25 mg/2mL
InhalantRespiratory (inhalation).5 mg/2mL
Spray, meteredNasal32 ug/1
SuspensionRespiratory (inhalation).25 mg/2mL
SuspensionRespiratory (inhalation).5 mg/2mL
Capsule, delayed release pelletsOral3 mg/1
Tablet, extended releaseOral9 mg
Capsule, extended releaseOral3 mg
Enema; kit; tabletRectal
Spray, meteredNasal100 mcg
Spray, meteredNasal64 mcg
Aerosol, powderRespiratory (inhalation)180 ug/1
Aerosol, powderRespiratory (inhalation)90 ug/1
SuspensionRespiratory (inhalation)0.25 mg
SuspensionRespiratory (inhalation)0.5 mg
SuspensionRespiratory (inhalation)1 mg/2mL
Aerosol, metered; powderRespiratory (inhalation)100 mcg
Aerosol, metered; powderRespiratory (inhalation)200 mcg
Aerosol, metered; powderRespiratory (inhalation)400 mcg
Aerosol, meteredNasal100 mcg
PowderNasal; Respiratory (inhalation)100 mcg
AerosolRespiratory (inhalation)
PowderRespiratory (inhalation)
SuspensionRespiratory (inhalation)0.125 mg
Aerosol, foamRectal28 mg/1
Tablet, extended releaseOral9 mg/1
Prices
Unit descriptionCostUnit
Budesonide micronized powder346.5USD g
DesOwen Lot w/Cetaphil Cream 0.05% Kit Box255.84USD box
Desowen 0.05% ointment kit217.2USD kit
Desowen 0.05% cream kit212.4USD kit
DesOwen 0.05% Lotion 118ml Bottle183.17USD bottle
Pulmicort Flexhaler 180 mcg/act Aerosol Inhaler163.34USD inhaler
Pulmicort 180 mcg flexhaler157.06USD inhaler
DesOwen 0.05% Lotion 59ml Bottle123.38USD bottle
Pulmicort Flexhaler 90 mcg/act Aerosol Inhaler121.98USD inhaler
Pulmicort 90 mcg flexhaler117.29USD inhaler
Rhinocort Aqua 32 mcg/act 8.6 gm Bottle111.96USD bottle
Rhinocort aqua nasal spray13.93USD g
Entocort EC 3 mg 24 Hour Capsule13.86USD capsule
Entocort ec 3 mg capsule12.22USD capsule
Budesonide 0.5 mg/2ml Suspension 2ml Plastic Container9.73USD plastic
Pulmicort 0.5 mg/2ml Suspension 2ml Plastic Container9.24USD plastic
Budesonide 0.25 mg/2ml Suspension 2ml Plastic Container9.07USD plastic
Entocort (115 Ml) 2.3 mg/enm Enema8.93USD enema
Pulmicort 1 mg/2 ml respule8.89USD ml
Pulmicort 0.25 mg/2ml Suspension 2ml Plastic Container7.85USD plastic
Pulmicort 0.5 mg/2 ml respule4.45USD ml
Pulmicort 0.25 mg/2 ml respul3.78USD ml
Desowen 0.05% cream2.43USD g
Pulmicort Nebuamp 0.5 mg/ml Suspension0.93USD ml
Pulmicort Turbuhaler 400 mcg/dose Metered Inhalation Powder0.62USD dose
Pulmicort Nebuamp 0.25 mg/ml Suspension0.46USD ml
Pulmicort Turbuhaler 200 mcg/dose Metered Inhalation Powder0.34USD dose
Pulmicort Nebuamp 0.125 mg/ml Suspension0.23USD ml
Pulmicort Turbuhaler 100 mcg/dose Metered Inhalation Powder0.17USD dose
Rhinocort Turbuhaler 100 mcg/dose Metered Dose Aerosol0.13USD dose
Mylan-Budesonide Aq 100 mcg/dose Metered Dose Spray0.1USD dose
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6423340No1993-11-152010-11-15Us
CA2071518No2002-11-122010-11-15Canada
US6598603Yes1999-06-232019-06-23Us
US6899099Yes1999-06-232019-06-23Us
US7524834Yes1999-05-112019-05-11Us
US7759328Yes2003-07-292023-07-29Us
US7897646Yes1999-03-092019-03-09Us
US8143239Yes2003-07-292023-07-29Us
US8461211Yes1999-03-092019-03-09Us
US8575137Yes2003-07-292023-07-29Us
US6123924No1997-09-262017-09-26Us
US7967011Yes2002-02-112022-02-11Us
US8616196Yes2009-10-072029-10-07Us
US8387615Yes2005-05-102025-05-10Us
US7587988Yes2006-10-102026-10-10Us
US7367333Yes1999-05-112019-05-11Us
US8528545Yes2009-04-162029-04-16Us
US8875699Yes2005-05-102025-05-10Us
US6027714No1998-01-092018-01-09Us
US7143764No1998-03-132018-03-13Us
US6142145No1998-05-082018-05-08Us
US6287540No1998-01-092018-01-09Us
US9320716No2000-06-092020-06-09Us
US9192581No2011-09-072031-09-07Us
US7410651No2000-06-092020-06-09Us
USRE43799No2000-06-092020-06-09Us
US8895064No2011-09-072031-09-07Us
US7431943No2000-06-092020-06-09Us
US9132093No2011-09-072031-09-07Us
US8784888No2000-06-092020-06-09Us
US8293273No2000-06-092020-06-09Us
US5914122No1995-12-192015-12-19Us
US9532954No2000-06-092020-06-09Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)226°CPhysProp
water solubilityinsolubleNot Available
logP1.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0457 mg/mLALOGPS
logP2.42ALOGPS
logP2.73ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)13.74ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area93.06 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity116.11 m3·mol-1ChemAxon
Polarizability47.11 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9872
Blood Brain Barrier+0.9533
Caco-2 permeable-0.6097
P-glycoprotein substrateSubstrate0.804
P-glycoprotein inhibitor INon-inhibitor0.5881
P-glycoprotein inhibitor IINon-inhibitor0.5911
Renal organic cation transporterNon-inhibitor0.7867
CYP450 2C9 substrateNon-substrate0.8488
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7337
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9075
CYP450 2D6 inhibitorNon-inhibitor0.9441
CYP450 2C19 inhibitorNon-inhibitor0.939
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8886
Ames testNon AMES toxic0.9117
CarcinogenicityNon-carcinogens0.9466
BiodegradationNot ready biodegradable0.9759
Rat acute toxicity2.1601 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9483
hERG inhibition (predictor II)Non-inhibitor0.5627
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03k9-1794300000-d4cdef973973a6b24ba4
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00dj-3950000000-8e98d604876730f53851

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxo delta-1,4-steroids / 11-beta-hydroxysteroids / Delta-1,4-steroids / Alpha-hydroxy ketones / 1,3-dioxolanes / Secondary alcohols / Cyclic ketones / Cyclic alcohols and derivatives
show 5 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / Pregnane-skeleton / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / Oxosteroid / Delta-1,4-steroid
show 17 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
11beta-hydroxy steroid, glucocorticoid, cyclic acetal, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, 21-hydroxy steroid (CHEBI:3207)

Targets

Details
1. Glucocorticoid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Zhang X, Moilanen E, Kankaanranta H: Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone. Eur J Pharmacol. 2000 Oct 20;406(3):325-32. [PubMed:11040338]
  2. Henriksson G, Norlander T, Forsgren J, Stierna P: Effects of topical budesonide treatment on glucocorticoid receptor mRNA down-regulation and cytokine patterns in nasal polyps. Am J Rhinol. 2001 Jan-Feb;15(1):1-8. [PubMed:11258648]
  3. Zhang X, Moilanen E, Kankaanranta H: Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis. Eur J Pharmacol. 2001 Nov 23;431(3):365-71. [PubMed:11730731]
  4. Kompella UB, Bandi N, Ayalasomayajula SP: Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1192-201. [PubMed:12601049]
  5. Kunz S, Sandoval R, Carlsson P, Carlstedt-Duke J, Bloom JW, Miesfeld RL: Identification of a novel glucocorticoid receptor mutation in budesonide-resistant human bronchial epithelial cells. Mol Endocrinol. 2003 Dec;17(12):2566-82. Epub 2003 Aug 14. [PubMed:12920235]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Jonsson G, Astrom A, Andersson P: Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos. 1995 Jan;23(1):137-42. [PubMed:7720517]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34